Optimizing Bone Health in Duchenne Muscular Dystrophy.

Area of Science:

• Pediatric Endocrinology
• Neuromuscular Disorders
• Bone Metabolism

Background:

• Duchenne muscular dystrophy (DMD) is an X-linked disorder causing progressive muscle weakness.
• Corticosteroids, the standard treatment for DMD, improve muscle strength but can worsen bone density.
• This leads to increased risk of fractures and impacts quality of life.

Purpose of the Study:

• To review current clinical issues concerning bone health in DMD patients.
• To discuss bone health screening methods and diagnostic tools.
• To explore treatment strategies for optimizing bone health.

Main Methods:

• Review of diagnostic studies including biochemical markers of bone turnover.
• Assessment of bone mineral density using dual-energy X-ray absorptiometry (DXA).
• Evaluation of spinal imaging techniques and bisphosphonate therapies.

Main Results:

• Corticosteroid therapy exacerbates osteoporosis in DMD patients.
• DXA and spinal imaging are key for assessing bone density and fractures.
• Bisphosphonates effectively increase bone mass and are used for symptomatic patients.

Conclusions:

• Optimizing bone health is crucial for managing DMD.
• Comprehensive screening and timely intervention with bisphosphonates can mitigate fracture risk.
• Further research into bone health management in DMD is warranted.